News

GALILEO is a sham-controlled pivotal trial investigating the efficacy and safety of aflibercept (Eylea, Bayer/Regeneron Pharmaceuticals) for the treatment of macular edema secondary to central retinal vein occlusion. Primary and secondary efficacy analyses after 6 months of routine monthly injections show consistent statistically significant treatment benefits.

This video animation demonstrates how the Argus II Retinal Prosthesis System (Second Sight Medical Products Inc.) operates.

This video testimonial features a male patient from Manchester, England, who received the Argus II Retinal Prosthesis System (Second Sight Medical Products Inc.) in 2009.

Optovue has received 510(k) clearance for the iCam Non-Mydriatic compact fundus camera, which produces 45° color fundus images of the eye as well as external ocular structures.

Regeneron Pharmaceuticals Inc. and Bayer HealthCare have initiated a new phase III trial to evaluate aflibercept (Eylea) injection in the treatment of DME in Russia and Asia.

The World Health Organization has approved the INN ”auriclosene” for NovaBay Pharmaceuticals Inc.’s lead Aganocide compound NVC-422 topical antimicrobial compound.

A glaucoma specialist discusses surgical treatment options in patients with painful blebs.

The Victus Femtosecond Laser Platform from Bausch + Lomb has received 510(k) clearance from the FDA for the creation of penetrating arcuate cuts/incisions in the cornea.

Optovue has received FDA 510(k) clearance for the Normative Database for the iVue spectral-domain optical coherence tomography (SD-OCT) system.

Refresh Optive Advanced Preservative-Free Lubricant Eye Drops (Allergan) work on all three layers of the tear film to relieve dry eye symptoms.

Laser refractive cataract surgery may offer more advantages to a clinical practice than LASIK; it provides a gentler surgical touch and the refractive results are more reproducible and improved.

Limitations associated with diagnosis of retinopathy of prematurity (ROP) by performing bedside indirect ophthalmoscopy are fueling interest in the use of telemedicine.

LASIK eye surgery inventor Gholam Peyman, MD, has been awarded the National Medal of Technology and Innovation, the highest honor bestowed on an American innovator.

Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has entered into a research collaboration agreement for posterior ocular diseases.

Hardware and software upgrades for Alcon’s Infiniti Vision System include the Intrepid AutoSert IOL injector, which enables automated delivery of the IOL.

A study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy in eyes with vitreous hemorrhage from PDR.

Acrylic, apodized diffractive multifocal lenses achieve good uncorrected vision with a high rate of spectacle independence in two prospective studies.

A new moist towlette from Bio-Tissue Inc. contains Cliradex, a preparation derived from tea-tree oil that can be used for regular eyelash and eyelid skin cleansing.

Bausch + Lomb has initiated its phase III clinical program of latanoprostene bunod (licensed by Nicox S.A.) for the reduction of IOP in glaucoma or ocular hypertension.

Bausch + Lomb (B + L) has issued a Class I recall of cannulas packed in sodium hyaluronate ophthalmic viscosurgical device (Amvisc).

Welch Allyn has received 510(k) clearance from the FDA for the Welch Allyn iExaminerT, which allows providers to manipulate images using the iPhone 4 or 4S.

Bausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.

Normal variation in intrasubject central corneal pachymetry was analyzed in groups of patients from eight countries who were undergoing refractive surgery. The data suggest a threshold to use in refractive surgery screening.

A dramatic shift is starting to transform the practice of surgery in glaucoma. While trabeculectomy and trab-like procedures show steady, evolutionary improvements, three new types of surgery are moving interventional care from a last resort to front-line therapy, said Ike K. Ahmed, MD, FRCSC, assistant professor at the University of Toronto, Ontario.